Netherton Syndrome Clinical Trial
Official title:
Defining the Skin and Blood Biomarkers of Ichthyosis
Ichthyosis is a group of genetic skin disorders that present with dry, thickened, scaly, or flaky skin. As of today, there is no cure or treatment. Doctors can only treat the dry skin with different types of emollients to soften the scale. A deeper understanding of this disease is required to develop better treatments. There are different types of cells and cell-produced signals (biomarkers) that are being studied in order to help find these new treatments. Looking at biomarkers has been successful in helping us to understand other skin disorders better. The purpose of this study is to determine which blood and skin biomarkers characterize ichthyosis. Hypothesis: We predict that the biomarkers correlating with disease activity in Netherton syndrome will be different than the biomarkers found to correlate with the lamellar and other ichthyosis phenotype.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | December 31, 2025 |
Est. primary completion date | December 31, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 1 Year to 60 Years |
Eligibility | Inclusion Criteria: - Control and ichthyosis subjects may be of either sex and must be between 1-60 years of age at the time of enrollment - Ichthyosis subjects include individuals with a diagnosis Netherton syndrome, lamellar ichthyosis, or other ichthyosis subtypes - Ichthyosis subjects should not have administered systemic immunosuppressant therapy in the month before the study - Ichthyosis subjects should not use topical immunosuppressants in the week before the study - Ichthyosis subjects should not have applied emollients to the planned biopsy sites within 12 hours before biopsy, but can be applied elsewhere - Controls may have no inflammatory disease, atopy, or obvious xerosis (urticaria, food allergy, allergic rhinitis or conjunctivitis, asthma) - Controls for skin sampling may have no observable abnormality in the sampled skin and, to further assure the normality of the "normal" skin edges, must not have evidence of inflammation or epidermal change in the lesion to be surgically removed - Subjects and guardians of minors must sign the approved IRB consent form(s) prior to initiation of the study protocol Exclusion Criteria: - Subjects who are unable to give informed consent or assent - Subjects who administered anti-inflammatory systemic and topical therapy or emollients that do not comply with inclusion criteria prior to blood and biopsy sampling - Subjects whose main diagnosis is deemed unsafe by the study investigator for study participation |
Country | Name | City | State |
---|---|---|---|
United States | Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago | Illinois |
United States | Northbrook Lurie Children's Outpatient Clinic | Chicago | Illinois |
United States | Northwestern University | Chicago | Illinois |
United States | Icahn School of Medicine at Mount Sinai | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Northwestern University | Galderma R&D, Icahn School of Medicine at Mount Sinai |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cellular infiltrates | We will examine your skin and blood samples for various immune cells known to be involved in ichthyosis. | One year | |
Primary | Gene expression | We will examine your skin and blood samples for various genes known to contribute to ichthyosis by analyzing RNA and cytokines. | One year | |
Secondary | Correlation of biomarkers to quality of life | We will analyze the blood and tissue biomarkers to determine whether they are comparable to quality of life and itch (pruritus) measures. | One year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05979831 -
A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome
|
Phase 1/Phase 2 | |
Completed |
NCT00208026 -
Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome
|
Phase 1/Phase 2 | |
Completed |
NCT05583669 -
A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01428297 -
A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome
|
Phase 1 | |
Recruiting |
NCT05856526 -
A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome
|
Phase 2/Phase 3 | |
Recruiting |
NCT05789056 -
Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome
|
Phase 2/Phase 3 | |
Recruiting |
NCT05521438 -
Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome
|
Phase 2/Phase 3 | |
Completed |
NCT05388903 -
A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT06137157 -
Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome
|
Phase 1 | |
Not yet recruiting |
NCT05902663 -
Natural History of Netherton Syndrome
|
||
Recruiting |
NCT04244006 -
A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome
|
Phase 2/Phase 3 | |
Completed |
NCT02113904 -
Clinical Trial Using Humira in Netherton Syndrome
|
Phase 2 | |
Recruiting |
NCT05211830 -
A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton Syndrome
|
Phase 1/Phase 2 | |
Completed |
NCT03041038 -
The Efficacy and Safety of Secukinumab in Patients With Ichthyoses
|
Phase 2 | |
Recruiting |
NCT02081313 -
Natural History and Biological Study of Netherton Syndrome
|
N/A | |
Recruiting |
NCT01545323 -
Gene Therapy for Netherton Syndrome
|
Phase 1 |